Welcome to our dedicated page for Axsome Therapeut SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Axsome Therapeutics, Inc. (NASDAQ: AXSM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer focused on central nervous system (CNS) conditions, Axsome uses its SEC reports to communicate financial results, product revenue for AUVELITY, SUNOSI, and SYMBRAVO, and updates on its development pipeline, which includes programs such as AXS-05, AXS-12, AXS-14, solriamfetol in new indications, and AZD7325.
Among the filings, Form 8-K current reports are especially relevant for tracking material events. For example, Axsome has filed 8-Ks to furnish press releases announcing quarterly financial results and to disclose updates such as the receipt of a Paragraph IV Certification Notice Letter regarding a proposed generic version of SYMBRAVO. These documents help investors understand how clinical progress, intellectual property developments, and commercial performance affect the company.
In addition to 8-Ks, investors typically review Axsome’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed discussions of net product revenue, research and development spending, selling and administrative expenses, risk factors, and descriptions of the company’s CNS portfolio and pipeline. Proxy statements and, when applicable, Forms 3, 4, and 5 can provide information on insider holdings and transactions, while registration statements and prospectuses outline capital-raising activities.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-Ks, 10-Qs, and major 8-Ks in plain language. Real-time EDGAR updates help ensure that new Axsome filings appear promptly, and AI-generated highlights can make it easier to locate information on topics such as AXS-05’s regulatory status, AXS-12’s Orphan Drug Designation, or revenue trends for AUVELITY, SUNOSI, and SYMBRAVO without reading every page of the underlying filing.
Axsome Therapeutics, Inc. filed a Form 8-K to report that it issued a press release titled “Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue.” The company is furnishing the press release as Exhibit 99.1 under Item 2.02, covering results of operations and financial condition, and also referencing it under Item 8.01 as an other event.
The company specifies that the information in Item 2.02, including Exhibit 99.1, is being furnished rather than filed, so it is not subject to liability under Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings unless specifically stated. The exhibit list confirms the press release and the related cover page data file as the primary attachments.
Axsome Therapeutics insider activity shows CEO Herriot Tabuteau exercising stock options and selling the resulting shares under a pre-approved Rule 10b5-1 trading plan. On January 5, 2026, he exercised 78,703 options at
AXSM insider plans a Rule 144 sale of common stock. A notice was filed to sell 31,261 shares of AXSM common stock through Goldman Sachs & Co. LLC on or about 01/07/2026 on the NASD, with an aggregate market value of $5,335,940.09. The filing lists 50,412,640 AXSM common shares outstanding.
The 31,261 shares were originally acquired on 05/27/2016 as compensation via stock options from the issuer, and will be sold through a cashless exercise and same-day sale. Over the past three months, the same seller, Herriot Tabuteau, has reported multiple AXSM common stock sales, including 89,824 shares on 11/03/2025 for $11,902,021.33 and 29,450 shares on 01/06/2026 for $5,074,991.87.
A holder of common stock in AXSM has filed a Rule 144 notice to sell 29,450 shares through Goldman Sachs & Co. LLC, with an aggregate market value of $5,061,866. The shares are expected to be sold on or about January 6, 2026 on the NASD market.
The securities being sold were acquired on May 27, 2016 as compensation in the form of stock options from the issuer, and the planned sale is described as a cashless exercise with same-day sale. The form also lists prior sales over the past three months by Herriot Tabuteau, including individual transactions such as 89,824 shares of common stock sold on November 3, 2025 for gross proceeds of $11,902,021.33 and 41,920 shares sold on January 5, 2026 for $7,227,116.99.
Axsome Therapeutics (AXSM) disclosed insider transactions by its Chief Executive Officer, who is also a Director and 10% Owner. On November 3–5, 2025, the executive exercised stock options and sold the underlying shares pursuant to a pre‑approved Rule 10b5‑1 plan.
Exercises and related sales: on 11/03, 91,705 shares were acquired via option exercise at $8.02 and sold at a weighted average of $132.34 (range $124.16–$137.59). On 11/04, 50,459 shares were exercised at $8.02 and sold at a weighted average of $133.79 (range $131.50–$135.90). On 11/05, 21,775 shares were exercised at $8.02 and sold at a weighted average of $134.49 (range $131.60–$135.49). The filing notes the exercises were necessary due to approaching the options’ 10‑year expiration.
Following the reported transactions, the executive directly held 7,229 shares and indirectly held 7,344,500 shares through an entity over which he has voting and dispositive power.
Axsome Therapeutics (AXSM) reported Q3 2025 results showing strong top-line growth while continuing to invest in commercialization. Total revenues were
Operating expenses rose to
Axsome ended the quarter with
Axsome Therapeutics furnished a press release announcing financial results for the three months ended September 30, 2025, along with an operations update. The release is attached as Exhibit 99.1 and, under General Instruction B.2, is furnished and not deemed filed. The company also filed an updated corporate presentation as Exhibit 99.2 and posted it to its website.
Axsome Therapeutics, Inc. Chief Executive Officer and director Herriot Tabuteau exercised a series of stock options that were expiring and sold the resulting shares under a pre-approved 10b5-1 plan between
Axsome Therapeutics, Inc. (AXSM) submitted a Rule 144 notice reporting a proposed sale of 12,774 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $1,516,401.54. The filer reports the shares were acquired on 05/27/2016 as compensation via stock options and that the planned sale method is a cashless exercise/same-day sale.
The form also lists multiple sales by the same person during the past three months: 09/12/2025 (27,907 shares), 09/15/2025 (15,254 shares), 09/16/2025 (19,719 shares), 10/06/2025 (19,220 shares), and 10/07/2025 (13,390 shares), with individual gross proceeds shown for each transaction. The notice includes the required certification that the seller is not aware of material nonpublic information about the issuer.
Axsome Therapeutics, Inc. insider filing reports a proposed sale of 13,390 shares of common stock through Goldman Sachs & Co. LLC with an aggregate market value of
The notice also discloses multiple insider sales in the prior three months by Herriot Tabuteau: 19,220 shares on